secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001641172-25-015338
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte renames to Insight Molecular Diagnostics (iMDx), ticker changes to IMDX on June 18
--------------------------------------------------------------------------------

- Company changed name from Oncocyte Corp to Insight Molecular Diagnostics Inc. effective June 13, 2025.
- Stock ticker changes from OCX to IMDX, effective before market open on June 18, 2025.
- Principal executive office relocated from Irvine, CA to Nashville, TN; CLIA lab already in Nashville.
- Product rebranding: VitaGraft Kidney (LDT) → GraftAssureCore, RUO kit → GraftAssureIQ, future IVD kit → GraftAssureDx.
- CEO letter reports progress toward FDA submission of transplant rejection test kit; three top-10 US transplant centers engaged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/0001641172-25-015338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer